🏭 The multi-product facility doubles the company’s global capacity and focuses on the commercial production of complex molecules.
🔬 The production line includes four new 2,000L single-use bioreactors and adds 22,000 square feet of cleanroom space.
🇺🇸 CEO Benedikt von Braunmühl highlights the company’s strong capabilities in the US.
🚀 Rentschler Biopharma contributed to nearly 25% of FDA-approved biopharmaceuticals in 2023.
Introduction:
Rentschler Biopharma has announced that its new production line in Milford, Massachusetts is now fully operational. The facility focuses on commercial production of highly complex molecules and has added 22,000 square feet of manufacturing cleanroom space, as well as four new 2,000L single-use bioreactors. The new production line doubles Rentschler Biopharma’s global cGMP capacity and emphasizes the company’s strong capabilities in the United States.
- The new production line of Rentschler Biopharma in Milford, Massachusetts is now fully operational.
- The facility focuses on commercial production of highly complex molecules and has added 22,000 square feet of manufacturing cleanroom space.
- The production line houses four new 2,000L single-use bioreactors, bringing the total production lines at the site up to three.
- The new production line doubles Rentschler Biopharma’s global cGMP capacity.
- This milestone highlights Rentschler Biopharma’s strong capabilities in the U.S., as it contributed to nearly 25% of the biopharmaceuticals approved by the FDA in 2023.
Conclusion:
Rentschler Biopharma’s newly operational production line in Massachusetts enhances its ability to produce highly complex molecules and increases its global cGMP capacity. This achievement signals the company’s strength and contributions to the biopharmaceutical industry in the U.S., as evidenced by its significant share in the FDA-approved biopharmaceuticals. The expanded facility positions Rentschler Biopharma to meet the growing demand for biopharmaceutical manufacturing.
